{"protocolSection": {"identificationModule": {"nctId": "NCT02230332", "orgStudyIdInfo": {"id": "AsthmaNet 009"}, "secondaryIdInfos": [{"id": "U10HL098115", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U10HL098115"}], "organization": {"fullName": "Milton S. Hershey Medical Center", "class": "OTHER"}, "briefTitle": "Alendronate to Prevent Loss of Bronchoprotection in Asthma", "officialTitle": "Proof of Concept Study of Alendronate for Asthma", "acronym": "ALFA"}, "statusModule": {"statusVerifiedDate": "2017-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-01"}, "primaryCompletionDateStruct": {"date": "2016-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-08-29", "studyFirstSubmitQcDate": "2014-08-29", "studyFirstPostDateStruct": {"date": "2014-09-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-10-02", "resultsFirstSubmitQcDate": "2017-11-09", "resultsFirstPostDateStruct": {"date": "2017-12-14", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-12-13", "lastUpdatePostDateStruct": {"date": "2018-01-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "dave mauger", "investigatorTitle": "Professor of Public Health Sciences", "investigatorAffiliation": "Milton S. Hershey Medical Center"}, "leadSponsor": {"name": "Milton S. Hershey Medical Center", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Beta-2-agonists are effective in reducing airway narrowing in asthma and protecting against stimuli that produce bronchoconstriction. The combination of long-acting beta agonists (LABA) and inhaled corticosteroids (ICS) has become the most commonly used asthma controller medication class in the United States, but unfortunately, even when LABAs are added to ICS and used regularly, 58-81% of patients with asthma fail to achieve total control. Regular use of beta-agonists, both short and long-acting, reduces the ability of these agents to protect against the airway narrowing that occurs in asthma in response to bronchoconstrictor stimuli. We refer to this reduced effect as loss of bronchoprotection. In this proof of concept trial we aim to determine if alendronate, which diminishes beta-2 adrenergic receptor internalization, can reduce the loss of bronchoprotection that occurs with regular use of LABAs, even when used in combination with ICS."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 78, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Alendronate", "type": "EXPERIMENTAL", "description": "Alendronate in 10mg capsules taken once daily", "interventionNames": ["Drug: Alendronate"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo capsule taken once daily", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Alendronate", "armGroupLabels": ["Alendronate"], "otherNames": ["Fasomax"]}, {"type": "DRUG", "name": "Placebo", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Salmeterol Protected Methacholine Challenge PC20", "description": "Following administration of Salmeterol, the concentration of Methacholine required to produce a 20% drop in FEV1 - measured in mg/ml and reported on log base 2 scale.", "timeFrame": "8 weeks after randomization"}], "secondaryOutcomes": [{"measure": "Peripheral Blood Mononuclear Cell ADRB2 Cell Surface Density", "timeFrame": "8 weeks after randomization"}, {"measure": "Beta-2 Adrenergic Receptor Agonist-induced cAMP Production", "description": "Peripheral blood mononuclear cells cAMP concentrations measured using isoproterenol (ISO) as a beta-2 adrenergic receptor agonist, and using phosphate buffered saline (PBS) as a positive control. The outcome is expressed as the ratio of cAMP concentration using ISO relative to cAMP concentration using PBS.", "timeFrame": "8 weeks after randomization"}], "otherOutcomes": [{"measure": "Salivary Alpha Amylase Ratio (Post-Salmeterol / Pre-Salmeterol)", "description": "Salivary Alpha Amylase (sAA) levels from saliva samples obtained through passive drooling, before and 1 hour after Salmeterol administration. The outcome is expressed as the ratio of the Post-Salmeterol to the Pre-Salmeterol sAA levels.", "timeFrame": "8 weeks after randomization"}, {"measure": "Asthma Control Test (ACT)", "description": "Asthma Control Test : Score calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled.", "timeFrame": "8 weeks after randomization"}, {"measure": "Fractional Exhaled Nitrix Oxide", "timeFrame": "8 weeks after randomization"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Clinical history consistent with moderate asthma for \\>1 year\n* Asthma is controlled with ICS, with an FP dose \u2264 1000mcg/day and \\>100mcg/day (or equivalent)\n* Able to perform reproducible spirometry according to ATS criteria\n* Baseline FEV1 \u2265 50% of predicted and \u22651L.\n* If FEV1 \\<80%, a minimum 12% increase in FEV1 post-bronchodilator or a MCh PC20 \u2264 8 mg/mL\n* If FEV1 \u226580%, a MCh PC20 \u2264 8 mg/mL\n* Salmeterol protected MCh \u2264 16 mg/mL\n\nExclusion Criteria:\n\n* Uncontrolled asthma, as suggested by an ACT score \\<18 while on high-dose ICS (FP daily dose \\>500mcg or equivalent)\n* Non-ICS controller medication or LABA use within 4 weeks of study entry.\n* Contraindications to use of bisphosphonates: history of intolerance to bisphosphonates, history of esophageal ulcers, history of hematemesis, uncontrolled gastro-esophageal reflux disease, inability to stay erect for 30 minutes after oral drug, history of osteonecrosis of the jaw, dental extraction or root canal in prior 8 weeks, or anticipated during the study\n* Calculated GFR of less than 35 mL/min\n* History of smoking (cigarettes, cigars, pipes, marijuana or any other substances) within the past 1 year, or \\> 10 pack-years total if \u2265 18 years of age\n* Systemic corticosteroid treatment for any condition within 4 weeks of enrollment at Visit 1, history of significant asthma exacerbation requiring systemic corticosteroids within 4 weeks of Visit 1 or more than five courses of systemic corticosteroids in the past year, history of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure within the last 2 years\n* History of a respiratory tract infection within 4 weeks of Visit 1\n* Receiving hyposensitization therapy other than an established maintenance regimen defined as a continuous regimen for \u2265 3 months prior to enrollment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Juan Carlos Cardet, MD", "affiliation": "Brigham and Women's Hospital", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "University of Arizona College of Medicine", "city": "Tucson", "state": "Arizona", "zip": "85724", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "University of California - San Francisco", "city": "San Francisco", "state": "California", "zip": "94143", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "National Jewish Health", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Northwestern Memorial Hospital", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "University of Illinois at Chicago", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "University of Chicago", "city": "Chicago", "state": "Illinois", "zip": "60637", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Brigham & Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Washington University", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Wake Forest University Health Sciences", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "University of Wisconsin", "city": "Madison", "state": "Wisconsin", "zip": "53972", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "referencesModule": {"references": [{"pmid": "30872116", "type": "DERIVED", "citation": "Cardet JC, Jiang X, Lu Q, Gerard N, McIntire K, Boushey HA, Castro M, Chinchilli VM, Codispoti CD, Dyer AM, Holguin F, Kraft M, Lazarus S, Lemanske RF, Lugogo N, Mauger D, Moore WC, Moy J, Ortega VE, Peters SP, Smith LJ, Solway J, Sorkness CA, Sumino K, Wechsler ME, Wenzel S, Israel E; AsthmaNet Investigators. Loss of bronchoprotection with ICS plus LABA treatment, beta-receptor dynamics, and the effect of alendronate. J Allergy Clin Immunol. 2019 Aug;144(2):416-425.e7. doi: 10.1016/j.jaci.2019.01.049. Epub 2019 Mar 11."}], "seeAlsoLinks": [{"label": "AsthmaNet home page", "url": "http://asthmanetresearch.org/"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with persistent asthma were first treated with fluticasone propionate 250mcg twice daily for 2 weeks during the run-in. Most of the participants who were not randomized did not meet the Salmeterol Protected Methacholine Challenge inclusion criterion.", "recruitmentDetails": "Eligible participants were recruited from the community between January 2015 and May 2016 at 9 U.S. sites from the NHLBI AsthmaNet research network.", "groups": [{"id": "FG000", "title": "Alendronate", "description": "Alendronate in 10mg capsules taken once daily\n\nAlendronate"}, {"id": "FG001", "title": "Placebo", "description": "Placebo capsule taken once daily\n\nPlacebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "40"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "39"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Alendronate", "description": "Alendronate in 10mg capsules taken once daily\n\nAlendronate"}, {"id": "BG001", "title": "Placebo", "description": "Placebo capsule taken once daily\n\nPlacebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "78"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.3", "spread": "13.1"}, {"groupId": "BG001", "value": "39.3", "spread": "12.3"}, {"groupId": "BG002", "value": "38.8", "spread": "12.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "47"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "31"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "45"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "23"}]}]}, {"title": "Asian/Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}]}, {"title": "Hispanic or Latio", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "78"}]}]}]}, {"title": "Asthma Control Test score", "description": "Asthma Control Test : Score calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled.", "paramType": "MEAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "21", "lowerLimit": "18", "upperLimit": "23"}, {"groupId": "BG001", "value": "21", "lowerLimit": "19", "upperLimit": "23"}, {"groupId": "BG002", "value": "21", "lowerLimit": "19", "upperLimit": "23"}]}]}]}, {"title": "FEV1 - percent of predicted", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent of predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "81.3", "spread": "14.9"}, {"groupId": "BG001", "value": "83.1", "spread": "14.0"}, {"groupId": "BG002", "value": "82.2", "spread": "14.4"}]}]}]}, {"title": "Salmeterol Protected Methcholine PC20", "description": "During the challenge, the patient inhales methacholine aerosols in increasing concentrations. Spirometry is performed before and after each methacholine dose, and the results are reported as a percent decrease in FEV1 from baseline for each increasing dose of methacholine. A positive reaction to methacholine is a 20% fall in FEV1, and the provocative concentration that causes a positive reaction (the PC20) is used to indicate the level of airway hyperresponsiveness. Smaller numbers indicate greater airway hyperresponsiveness.", "paramType": "GEOMETRIC_MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/ml", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.4", "spread": "0.8"}, {"groupId": "BG001", "value": "3.7", "spread": "1"}, {"groupId": "BG002", "value": "4.5", "spread": "0.9"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Salmeterol Protected Methacholine Challenge PC20", "description": "Following administration of Salmeterol, the concentration of Methacholine required to produce a 20% drop in FEV1 - measured in mg/ml and reported on log base 2 scale.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/ml on log base 2 scale", "timeFrame": "8 weeks after randomization", "groups": [{"id": "OG000", "title": "Alendronate", "description": "Alendronate in 10mg capsules taken once daily\n\nAlendronate"}, {"id": "OG001", "title": "Placebo", "description": "Placebo capsule taken once daily\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "lowerLimit": "1.1", "upperLimit": "2.5"}, {"groupId": "OG001", "value": "1.7", "lowerLimit": "1.1", "upperLimit": "2.3"}]}]}]}, {"type": "SECONDARY", "title": "Peripheral Blood Mononuclear Cell ADRB2 Cell Surface Density", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "number of receptors per cell", "timeFrame": "8 weeks after randomization", "groups": [{"id": "OG000", "title": "Alendronate", "description": "Alendronate in 10mg capsules taken once daily\n\nAlendronate"}, {"id": "OG001", "title": "Placebo", "description": "Placebo capsule taken once daily\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1680", "lowerLimit": "1359", "upperLimit": "2076"}, {"groupId": "OG001", "value": "1863", "lowerLimit": "1473", "upperLimit": "2358"}]}]}]}, {"type": "SECONDARY", "title": "Beta-2 Adrenergic Receptor Agonist-induced cAMP Production", "description": "Peripheral blood mononuclear cells cAMP concentrations measured using isoproterenol (ISO) as a beta-2 adrenergic receptor agonist, and using phosphate buffered saline (PBS) as a positive control. The outcome is expressed as the ratio of cAMP concentration using ISO relative to cAMP concentration using PBS.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ratio", "timeFrame": "8 weeks after randomization", "groups": [{"id": "OG000", "title": "Alendronate", "description": "Alendronate in 10mg capsules taken once daily\n\nAlendronate"}, {"id": "OG001", "title": "Placebo", "description": "Placebo capsule taken once daily\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.9", "lowerLimit": "4.7", "upperLimit": "7.5"}, {"groupId": "OG001", "value": "5.9", "lowerLimit": "4.9", "upperLimit": "7.2"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Salivary Alpha Amylase Ratio (Post-Salmeterol / Pre-Salmeterol)", "description": "Salivary Alpha Amylase (sAA) levels from saliva samples obtained through passive drooling, before and 1 hour after Salmeterol administration. The outcome is expressed as the ratio of the Post-Salmeterol to the Pre-Salmeterol sAA levels.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ratio", "timeFrame": "8 weeks after randomization", "groups": [{"id": "OG000", "title": "Alendronate", "description": "Alendronate in 10mg capsules taken once daily\n\nAlendronate"}, {"id": "OG001", "title": "Placebo", "description": "Placebo capsule taken once daily\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.6", "lowerLimit": "1.4", "upperLimit": "1.9"}, {"groupId": "OG001", "value": "1.6", "lowerLimit": "1.3", "upperLimit": "1.9"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Asthma Control Test (ACT)", "description": "Asthma Control Test : Score calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "8 weeks after randomization", "groups": [{"id": "OG000", "title": "Alendronate", "description": "Alendronate in 10mg capsules taken once daily\n\nAlendronate"}, {"id": "OG001", "title": "Placebo", "description": "Placebo capsule taken once daily\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.2", "lowerLimit": "21.2", "upperLimit": "23.2"}, {"groupId": "OG001", "value": "22.2", "lowerLimit": "21.4", "upperLimit": "23.1"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Fractional Exhaled Nitrix Oxide", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "parts per billion", "timeFrame": "8 weeks after randomization", "groups": [{"id": "OG000", "title": "Alendronate", "description": "Alendronate in 10mg capsules taken once daily\n\nAlendronate"}, {"id": "OG001", "title": "Placebo", "description": "Placebo capsule taken once daily\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.8", "lowerLimit": "12.9", "upperLimit": "21.9"}, {"groupId": "OG001", "value": "15.4", "lowerLimit": "11.7", "upperLimit": "20.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "8 weeks", "eventGroups": [{"id": "EG000", "title": "Alendronate", "description": "Alendronate in 10mg capsules taken once daily\n\nAlendronate", "deathsNumAffected": 0, "deathsNumAtRisk": 38, "seriousNumAffected": 0, "seriousNumAtRisk": 38, "otherNumAffected": 9, "otherNumAtRisk": 38}, {"id": "EG001", "title": "Placebo", "description": "Placebo capsule taken once daily\n\nPlacebo", "deathsNumAffected": 0, "deathsNumAtRisk": 40, "seriousNumAffected": 2, "seriousNumAtRisk": 40, "otherNumAffected": 13, "otherNumAtRisk": 40}], "seriousEvents": [{"term": "Viral Pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "GI Bleed", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}], "otherEvents": [{"term": "Esophageal reflux", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Acute nasopharyngitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Acute sinusitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Acue Upper Respiratory Infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 40}]}, {"term": "asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 40}]}, {"term": "thrush", "organSystem": "Infections and infestations", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "headache", "organSystem": "General disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 40}]}, {"term": "Heartburn", "organSystem": "General disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Nausea alone", "organSystem": "General disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 5, "numAffected": 3, "numAtRisk": 40}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "David Mauger, PhD", "organization": "Penn State University Dept of Public Health Sciences", "email": "dmauger@psu.edu", "phone": "717.531.3584"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019386", "term": "Alendronate"}], "ancestors": [{"id": "D000050071", "term": "Bone Density Conservation Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M21353", "name": "Alendronate", "asFound": "Vitamin B", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}